Pacira Pharmaceuticals Inc (PCRX) : Bouchey Financial Group Ltd has sold out all of its stake in Pacira Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Jul 15, 2016 with the SEC. The investment management company has sold out 4,550 shares of Pacira Pharmaceuticals Inc which is valued at $165,029.
Other Hedge Funds, Including , Arcadia Investment Management Corpmi added PCRX to its portfolio by purchasing 633 company shares during the most recent quarter which is valued at $22,959. Pacira Pharmaceuticals Inc makes up approx 0.01% of Arcadia Investment Management Corpmi’s portfolio. Cutler Group Lp sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 1,956 shares of PCRX which is valued $68,030. Franklin Street Advisors Inc Nc sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 12,325 shares of PCRX which is valued $428,664.
Pacira Pharmaceuticals Inc closed down -0.52 points or -1.41% at $36.27 with 3,65,080 shares getting traded on Monday. Post opening the session at $36.65, the shares hit an intraday low of $35.91 and an intraday high of $36.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 2, 2016. Analyst had a consensus of $0.09. The company had revenue of $65.50 million for the quarter, compared to analysts expectations of $66.82 million. The company’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.
Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Pacira Pharmaceuticals Inc was Downgraded by Brean Capital to ” Hold” on Jul 1, 2016. Shares were Reiterated by Wedbush on May 25, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $113 .Shares were Reiterated by Mizuho on May 3, 2016 to “Buy” and Lowered the Price Target to $ 64 from a previous price target of $71 .
Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.